Cargando…

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges

Second-generation androgen receptor axis-targeted (ARAT) agents, namely abiraterone and enzalutamide, enable stronger blockade of the androgen receptor (AR) axis and longer survival of men with castration-resistant prostate cancer (CRPC). However, the extent of the improved survival remains insuffic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kita, Yuki, Goto, Takayuki, Akamatsu, Shusuke, Yamasaki, Toshinari, Inoue, Takahiro, Ogawa, Osamu, Kobayashi, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210307/ https://www.ncbi.nlm.nih.gov/pubmed/30248934 http://dx.doi.org/10.3390/cancers10100345

Ejemplares similares

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
por: Sumiyoshi, Takayuki, et al.
Publicado: (2019)

Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
por: Makino, Yuki, et al.
Publicado: (2022)

Author Correction: Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
por: Makino, Yuki, et al.
Publicado: (2022)

Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation
por: Aizawa, Rihito, et al.
Publicado: (2019)

Arteriovenous fistula after robot‐assisted laparoscopic prostatectomy: A rare case report
por: Suzuki, Ryosuke, et al.
Publicado: (2019)

Consecutive Prostate Cancer Specimens Revealed Increased Aldo–Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer
por: Miyazaki, Yu, et al.
Publicado: (2019)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
por: Kobayashi, Takashi, et al.
Publicado: (2013)

Solitary recurrence of prostate cancer surrounded by seminal vesicle/vas deferens‐like epithelium
por: Takamori, Hajime, et al.
Publicado: (2020)

The Roles of Extracellular Vesicles in the Progression of Renal Cell Carcinoma and Their Potential for Future Clinical Application
por: Takeda, Masashi, et al.
Publicado: (2023)

Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies
por: Kita, Yuki, et al.
Publicado: (2019)

Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer
por: Sato, Genki Edward, et al.
Publicado: (2020)

Rapidly Progressive Bladder Cancer Diagnosed because of Spontaneous Bladder Rupture
por: Hagimoto, Hiroki, et al.
Publicado: (2022)

A narrative review of urinary phospholipids: from biochemical aspect towards clinical application
por: Li, Xin, et al.
Publicado: (2021)

Functional and genomic characterization of patient‐derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma
por: Sakamoto, Hiromasa, et al.
Publicado: (2020)

Data processing on a comparative evaluation of the extraction and analysis procedures for urinary phospholipid and lysophospholipid using MALDI-TOF/MS
por: Li, Xin, et al.
Publicado: (2019)

Detection of von Hippel‐Lindau gene mutation in circulating cell‐free DNA for clear cell renal cell carcinoma
por: Sumiyoshi, Takayuki, et al.
Publicado: (2021)

Extracellular vesicles secreted from bone metastatic renal cell carcinoma promote angiogenesis and endothelial gap formation in bone marrow in a time-dependent manner in a preclinical mouse model
por: Takeda, Masashi, et al.
Publicado: (2023)

A 45,X/46,XY Male with Orchidopexy Diagnosed with Mixed Germ Cell Tumor After 21-year Follow-up
por: Kubota, Masashi, et al.
Publicado: (2017)

Ten‐year outcomes of whole‐pelvic intensity‐modulated radiation therapy for prostate cancer with regional lymph node metastasis
por: Nakamura, Kiyonao, et al.
Publicado: (2022)

Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
por: Terada, Naoki, et al.
Publicado: (2017)

Identification of the α2 chain of interleukin‐13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient‐derived xenograft models
por: Nagai, Takahiro, et al.
Publicado: (2022)

A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months
por: Shimizu, Kosuke, et al.
Publicado: (2022)

Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
por: Aizawa, Rihito, et al.
Publicado: (2022)

Successful surgical management of recurrent urachal adenocarcinoma: A case report
por: Somiya, Shinya, et al.
Publicado: (2020)

Up‐regulation of secretory leukocyte protease inhibitor in human samples might have a potential role of predicting prostate cancer recurrence and progression after surgery and hormonal therapy
por: Miyazaki, Yu, et al.
Publicado: (2022)

High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer
por: Li, Xin, et al.
Publicado: (2021)

Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
por: Inoue, Takahiro, et al.
Publicado: (2011)

Case Report: A Case of Renal Cell Carcinoma Unclassified With Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint Blockade
por: Takeda, Masashi, et al.
Publicado: (2022)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer
por: Murakami, Kaoru, et al.
Publicado: (2021)

Paraurachal paraganglioma
por: Tsuruta, Masafumi, et al.
Publicado: (2022)

Masked acute rejection of the graft kidney under the recovery of native kidneys in a patient who underwent simultaneous liver and kidney transplantation
por: Hattahara, Kodai, et al.
Publicado: (2020)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13
por: Okasho, Kosuke, et al.
Publicado: (2021)

IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab
por: Sakatani, Toru, et al.
Publicado: (2022)

Narrative review of challenges in the management of advanced neuroendocrine prostate cancer
por: Okasho, Kosuke, et al.
Publicado: (2021)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Robot-assisted partial nephrectomy for renal cell carcinoma in the isthmus of horseshoe kidney
por: Sawada, Atsuro, et al.
Publicado: (2022)

Incomplete sagittal septum of the bladder with cystolithiasis
por: Fujimoto, Takeru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eaae0bmguqfptembgakqpq2432